
Opinion|Videos|August 23, 2024
Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do you incorporate proactive management strategies into your practice setting?
- What challenges have you faced when integrating proactive management strategies into the clinical practice setting?
- What tools/resources would be helpful in overcoming these?
Advertisement
Related to this article

Data from the phase 1/2 ALKOVE-1 trial support the FDA approval of neladalkib in this non–small cell lung cancer population.

Alembic’s binimetinib 15-mg and 45-mg tablets, given with encorafenib, received final FDA approval for BRAF-mutant melanoma and NSCLC.

An NDA submission had been completed for zipalertinib plus chemotherapy in untreated EGFR exon 20 insertion–mutant NSCLC based on REZILIENT3 data.

A complete response letter was given to ivonescimab for patients with previously treated EGFR-mutated NSCLC.

Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.

An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.

The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs vs T-Cell-Redirecting Therapies at First Relapse in Relapsed/Refractory Multiple Myeloma
2
Why CAR T May Belong Before Bispecifics in Multiple Myeloma
3
How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?
4
Applying CELMoD Class-Level and Agent-Level Evidence to Treatment Selection in Relapsed/Refractory Multiple Myeloma
5

